In this episode Nolita connects with Ian McDonald, the CEO of Bright Minds Biosciences Inc.
Bright Minds harnesses decades of experience in the biology of the serotonergic system to understand the effect specific receptors have on the body. This new generation of highly targeted serotonergic drugs is able to reach specific patient populations that the compounds of today cannot. The team at Bright Minds consists of neuroscientists, drug developers and physicians who are tackling the big problems in mental health and neurology.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. Bright Minds is focused on developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious neuropsychiatry drugs into the clinic. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin. Bright Minds was selected to participate in two National Institutes of Health (“NIH”) Programs. These NIH collaborations are evaluating Bright Minds serotonin agonists for therapeutic potential in pain and in epilepsy.
Connect with Bright Minds Biosciences Inc.
Follow:
Join the Movement!
Social:
Crisis lines:
• Toronto Distress Centres: 416 408-4357 or 408-HELP • Gerstein Centre: 416 929-5200 • Spectra Helpline: 416 920-0497 or 905 459-7777 for Brampton and Mississauga residents
• Kids Help Phone: 1 800 668-6868; Languages: English and French
• Community Crisis Line Scarborough and Rouge Hospital: 416 495-2891 for 24/7 telephone crisis support.
• The Canada Suicide Prevention Service; 1-833-456-4566 (toll free) 24/7 or visit https://urldefense.com/v3/__http://www.crisisservicescanada.ca__;!!HMCOyEk!NJj5_4g_NrPcUlEwy-LHkBZ4xhphLllyycr-CSAGyZtGAd0BIq_lfCO4UTHG4DKmnXIzG58$ or text 45645
